Journal of cancer research and therapeutics最新文献

{"title":"Acoustically activated nanoplatforms achieve tumor regression by exacerbating tumor hypoxia.","authors":"Caixia Ling, Shanshan Ma, Mengqi Zhang, Danke Su, Zixuan Liang","doi":"10.4103/jcrt.jcrt_1838_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1838_24","url":null,"abstract":"<p><strong>Background: </strong>Rapid tumor proliferation can be mitigated by \"starving the cancer cells\" through nutrient and oxygen blood supply blockade to the tumor, which is a significant challenge in oncological treatment.</p><p><strong>Methods: </strong>We developed a multipathway nano platform designed to improve hypoxia-exacerbated cancer starvation therapy. This was achieved by co-loading the acoustic sensitizer-IR780-and the vascular disruptor-vadimezan (DMXAA)-into dendritic silica nanocarriers to establish acid-responsive nanoplatforms, termed DMXAA/IR780@SiO2 (DIS NPs), using a simple one-pot synthesis method. In vivo and in vitro experiments were conducted to determine the antitumor mechanisms of this nanomaterial.</p><p><strong>Results: </strong>In vitro cellular experiments revealed that reaching the acidic tumor microenvironment value with DMXAA/IR780@SiO2 degrades silica in DIS NPs, accompanied by the release of the drug, and the released DMXAA damaged blood vessels at the tumor site, thereby blocking oxygen and nutrient supplies. Concurrently, the acoustic sensitizer-IR780-released after the cleavage of DIS NPs generates reactive oxygen species under the action of ultrasound (US), thereby depleting oxygen, further aggravating tumor hypoxia, and damaging the mitochondria by disrupting the redox reaction, which ultimately triggers cellular damage and even death. Further, a significant therapeutic effect on tumors in vivo was observed when combined with ultrasound US therapy, demonstrating synergistic therapeutic effects in terms of acoustic dynamics and vascular disruption, as well as good biosafety.</p><p><strong>Conclusion: </strong>The DIS NPs exhibit a promising approach for hypoxia-exacerbated cancer starvation therapy, providing a potential new avenue for cancer treatment with demonstrated efficacy and biocompatibility.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"371-380"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization.","authors":"Shengyu Zhou, Qingfeng Lin, Junsheng Zhong, Jian Chen","doi":"10.4103/jcrt.jcrt_2250_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2250_24","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical value of transcatheter arterial chemoembolization (TACE) using a temperature-sensitive liquid embolic agent for the interventional treatment of primary hepatocellular carcinoma.</p><p><strong>Methods: </strong>The clinical data and follow-up results sourced from the First Affiliated Hospital of Fujian Medical University were retrospectively analyzed from February 2023 to May 2023. Clinical efficacy was assessed through follow-up imaging using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. In addition, adverse reactions and adverse events were observed and classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTC) version 3.0.</p><p><strong>Results: </strong>Among the 11 patients analyzed in this study, a total of 41 lesions were identified. The average maximum diameter of the lesions was 3.55 ± 1.88 cm (range: 1.70 cm-6.60 cm). One month postoperatively, the efficacy assessment revealed complete response (CR) in 1 case, partial response (PR) in 9 cases, stable disease (SD) in 1 case, and progression in 0 case. The objective response rate (CR + PR) was 90.91%, and the disease control rate (CR + PR + SD) was 100%. Postoperative adverse reactions were mostly of grade 1-2, including abdominal pain, bloating, fever, nausea, and vomiting.</p><p><strong>Conclusion: </strong>The use of temperature-sensitive liquid embolic agents loaded with lobaplatin for chemoembolization in the treatment of unresectable primary liver cancer is a safe and effective therapeutic modality.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"504-508"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upfront autologous hematopoietic stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma: A real-world multicenter study.","authors":"Zhi Guo, Xiaomin Xian, Xiaochen Xiang, Jun Wang, Zhiqiang Sun, Yueqiao Wang, Jing Xie, Jingye Meng, Yongqian Li, Min Zhou, Guowei Li, Bo Lu, Xiaojun Xu, Liang Wang, Qiang Wang","doi":"10.4103/jcrt.jcrt_2102_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2102_24","url":null,"abstract":"<p><strong>Background and purpose: </strong>The ability of autologous hematopoietic stem cell transplantation (ASCT) to improve the benefit of patients with high-risk diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) following induction chemotherapy is controversial. This multicenter real-world study aimed to explore the efficacy and safety of the rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen followed by consolidated ASCT therapy in newly diagnosed DLBCL.</p><p><strong>Methods: </strong>From June 2018 to June 2021, the clinical data of patients with high-risk DLBCL who reached CR after receiving the R-CHOP regimen from ten lymphoma diagnosis and treatment centers were analyzed. Patients were included in the R-CHOP+ASCT (with consolidated ASCT therapy, n = 60) and R-CHOP (follow-up without consolidated ASCT therapy, n = 60) groups. The efficacy in the two groups was compared by difference analysis, and the safety of R-CHOP+ASCT was analyzed.</p><p><strong>Results: </strong>Until June 2024, the median follow-up times for the R-CHOP+ASCT and R-CHOP groups were 44 (37.25-56) and 43.5 (38-52) months, respectively. Survivors were followed up for at least 36 months. In the R-CHOP+ASCT group, the 3-year disease-free survival (DFS) and overall survival (OS) rates were 89.7% and 96.7% and those in the R-CHOP group were 63.9% and 85.9%, respectively. The 3-year DFS rate in the R-CHOP+ASCT group was significantly higher than that in the R-CHOP group (89.7% vs 63.9%, P = 0.001); no significant difference was found in the 3-year OS rate between the R-CHOP+ASCT and R-CHOP groups (96.7% vs 85.9%, P = 0.113). The 5-year DFS and OS rates in the R-CHOP+ASCT group were 73.6% and 77.6% and those in the R-CHOP group were 56.5% and 81.1%, respectively. The 5-year DFS rate in the R-CHOP+ASCT group was significantly higher than that in the R-CHOP group (73.6% vs 56.5%, P = 0.009), whereas no significant difference was found in the 5-year OS rate between the R-CHOP+ASCT and R-CHOP groups (77.6% vs 81.1%, P = 0.246). In the Cox multifactorial analysis, discontinuous consolidated ASCT therapy, bone marrow invasion, and dual expression were poor prognostic factors that affect DFS [hazard ratio (HR), 5.710; 95% confidence interval (CI), 2.241-14.548, P < 0.001; HR, 4.324; 95% CI, 1.890-9.893, P = 0.001; HR, 2.565; 95% CI, 1.145-5.747, P = 0.022, respectively] and dual expression was a poor prognostic factor for OS (HR, 3.486; 95% CI, 1.300-9.344, P = 0.013). Grade IV myelosuppression after transplantation developed in the R-CHOP+ASCT group, and other common grade 3 or 4 treatment-related adverse events were infection and fever.</p><p><strong>Conclusion: </strong>For patients with newly diagnosed high-risk DLBCL, consolidated ASCT therapy can increase the DFS rate of those with CR status following the R-CHOP regimen, and the safety is controllable.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"447-456"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate changes in MRI signals after the MRI-guided microwave ablation of malignant liver tumors.","authors":"Jian Yang, Yunying Song, Jiwei Geng, Jikun Zhao, Bin Xiao, Hua Zhao, Zhengyu Lin, Derong Zhao","doi":"10.4103/jcrt.jcrt_1458_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1458_24","url":null,"abstract":"<p><strong>Objective: </strong>To observe the immediate changes in MRI signals after the MRI-guided microwave ablation of malignant liver tumors and to explore the pattern of immediate signal changes post-ablation.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 23 patients with 27 lesions who underwent MRI-guided liver microwave ablation at Baoshan people's Hospital from September 2022 to December 2023. The relationship between the changes in MRI signals and time post-ablation was studied. The first scan was performed immediately after ablation (designated as 0 min) and followed by scans at 3 min, 6 min, 10 min, 15 min, 20 min, and 30 min post-ablation. The signal characteristics that changed in each sequence after each scan were measured and recorded.</p><p><strong>Results: </strong>After ablation, the mean maximum diameter of the high-signal range in 27 T1WI ablation foci varied over a short period of time (0 min: 22.00 mm; at 3 min: 26.58 mm; at 6 min: 26.94 mm; at 10 min: 27.06 mm; at 15 min: 27.12mm; at 20 min: 27.16 mm; and at 30 min: 27.16 mm). The change from 0-10 min was statistically significant (t = -10.326, P < 0.001), whereas the change from 10-30 min was not statistically significant (t = -1.536, P = 0.068). And, the signal intensity increased over time. The signal intensity of the primary lesion remained unchanged while the range decreased. There were minimal differences in the range and intensity changes in the T2-weighted imaging (T2WI) sequence. In diffusion-weighted imaging (DWI), the lesions showed high-signal intensity pre-ablation, but in post-ablation, it exhibited a high-signal surrounding the ablation zone with iso-intense or mixed signals, and the apparent diffusion coefficient (ADC) value increased.</p><p><strong>Conclusion: </strong>The high-signal range observed in the T1WI sequence at the 10th min scan after the ablation completely reflected the true extent of the ablated foci, whereas the low-signal range in the T2WI sequence was stable and unchanged.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"435-441"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study on the safety and efficacy of a robotic-assisted navigation and positioning system in CT-guided percutaneous biopsy of thoracic and abdominal tumors.","authors":"Xiang You, Xiaoli Zhu, Qingjie Chen, Jin Chen, Huihuang Lin, Bingyu Huang, Dongyong Yang, Hongjie Hu, Zhengyu Lin","doi":"10.4103/jcrt.jcrt_1888_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1888_24","url":null,"abstract":"<p><strong>Objective: </strong>To compare the safety, accuracy, and application efficacy of a computed tomography (CT)-guided robotic-assisted navigation system and conventional CT-guided percutaneous puncture biopsy techniques for thoracic and abdominal tumor puncture biopsies.</p><p><strong>Methods: </strong>A total of 140 patients with thoracic or abdominal tumors who were scheduled to undergo CT-guided percutaneous puncture biopsy were randomly assigned to the robotic navigation system puncture group and the traditional step-by-step puncture group. Postoperative tissue specimens and pathological diagnosis results were obtained. The success rate of localization, number of adjustments, localization time, and number of CT scans were used as evaluation indicators. In addition, the surgical safety indicators were observed, and the homogeneity differences between the two groups were compared.</p><p><strong>Results: </strong>The robotic navigation group had significantly higher success rates of localization (84.1% vs. 43.7%), fewer adjustment times (1.51 ± 1.48 vs. 3.51 ± 3.05), and fewer CT scan times (4.99 ± 2.11 vs. 7.11 ± 3.74) than the traditional puncture group (P < 0.05). However, no statistically significant differences were observed in the localization times of chest operation and the occurrence of complications between the two groups.</p><p><strong>Conclusion: </strong>The robotic puncture navigation system improves the success rate of localization and reduces the number of puncture adjustments and CT scans; therefore, it is superior to the traditional step-by-step puncture method.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"389-394"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of the clinicopathological features and prognostic implications of invasive breast carcinoma of nonspecial type exhibiting HER2-low and HER2-zero expressions.","authors":"Yuanyuan Chen, Xin Ye, Jie Wang, Baosan Han","doi":"10.4103/jcrt.jcrt_277_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_277_24","url":null,"abstract":"<p><strong>Purpose: </strong>This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.</p><p><strong>Methods: </strong>Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.</p><p><strong>Results: </strong>Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).</p><p><strong>Conclusion: </strong>The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"425-434"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective review of treatment approach and outcomes for locally advanced head and neck squamous cell cancer.","authors":"Yidi Jin, Hao Jiang, Qian Sun, Feifan Li, Xiaohan Wu, Zhifei Huang","doi":"10.4103/jcrt.jcrt_1332_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1332_24","url":null,"abstract":"<p><strong>Background: </strong>We sought to provide clinicians with important insights into the best treatment plans for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) by examining the treatment trends and outcomes of the disease.</p><p><strong>Methods: </strong>Data pertaining to 158 patients with stage III to IVB LA-HNSCC who received treatment at our hospital from October 2019 to October 2021 were examined in this study. The clinical results of various treatment approaches were compared among the patients.</p><p><strong>Results: </strong>Of the 158 patients, 42 (26.6%) received definitive concurrent chemoradiotherapy (CCRT), 41 (36%) received induction chemotherapy (IC), and 95 (60.1%) underwent surgery. The 1-, 2-, and 3-year survival rates were 84.8%, 70.7%, and 59.3%, respectively, with a median follow-up of 36 months. No discernible difference in overall survival was observed between the CCRT and surgical groups (P = 0.397).</p><p><strong>Conclusions: </strong>The decision regarding definitive CCRT, IC followed by definitive CCRT, surgery followed by adjuvant CCRT, or radiotherapy for patients with LA-HNSCC should be made in consultation with the multidisciplinary team. Furthermore, the decision should take into account the patient's overall health and the diagnosis, stage, developmental tendency, preferences, and prognosis of the disease. The most suitable overall treatment strategy for the patient must be formulated.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"381-388"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.","authors":"Fangjie Ding, Junfeng Zhao, Xue Wu, Xiaoman Liu, Yunxing Yang, Ying Li, Lili Qiao, Yingying Zhang","doi":"10.4103/jcrt.jcrt_1279_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1279_24","url":null,"abstract":"<p><strong>Background: </strong>The necessity of postmastectomy radiotherapy (PMRT) following neoadjuvant chemotherapy (NAC) in patients with ypN0 breast cancer remains a controversial clinical issue. To elucidate this issue, the present study performed a systematic review and meta-analysis, focusing on studies of clinically lymph node-negative patients exhibiting a favorable pathologic response to NAC.</p><p><strong>Materials and methods: </strong>After a comprehensive literature search of PubMed and major oncology congress abstracts, 16 studies that met the inclusion criteria were included. A fixed or random effects model was used to assess the impact of PMRT on the local recurrence rate (LRR) and survival outcomes, where appropriate.</p><p><strong>Results: </strong>The pooled data from ten studies indicated that PMRT significantly reduced the LRR in patients with ypN0 breast cancer (risk ratio [RR], 0.52; 95% confidence interval [CI], 0.41-0.67, P < 0.00001). Moreover, a marginal increase in the overall survival (OS) rates was observed in nine studies (RR, 1.01; 95% CI, 1.00-1.02, P = 0.006), whereas no significant effect on disease-free survival (DFS) was found in six studies (RR, 1.01; 95% CI, 0.95-1.08, P = 0.72).</p><p><strong>Conclusions: </strong>Our findings suggest that PMRT is associated with reduced LRR and slightly improved OS in patients with ypN0 breast cancer. However, prospective studies are needed to provide more evidence and inform clinical decision-making.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"477-482"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research advances in FGL1/LAG3 for cancer diagnosis and treatment: From basics to clinical practice.","authors":"Keyao Hu, Guiming Zhang, Haitao Niu, Lijiang Sun","doi":"10.4103/jcrt.jcrt_2674_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2674_23","url":null,"abstract":"<p><strong>Abstract: </strong>Fibrinogen-like protein 1 (FGL1), a liver-secreted protein involved in proliferation and metabolism, and lymphocyte activation gene 3 (LAG3), an immune checkpoint receptor expressed on the surfaces of various activated immune cells, play critical roles in tumor immunology. Numerous studies have confirmed that FGL1 acts as a ligand for LAG3 and mediates immune evasion by tumor cells. This review aims to provide a comprehensive summary of the research progress in FGL1/LAG3 in terms of its expression, role in the tumor microenvironment, and clinical application. The expression and regulation of FGL1/LAG3 are influenced by multiple cytokines and signaling pathways. In the tumor microenvironment, FGL1/LAG3 modulates tumor cell proliferation, invasion, and migration through mechanisms such as epithelial-mesenchymal transition, gene methylation, oxygen metabolism, and lipid metabolism. FGL1/LAG3 can serve as a prognostic biomarker, independently or in combination with PD-L1/PD-1, and can be targeted using monoclonal antibodies, bi-specific antibodies, and dual-targeted vaccines to restore the proliferation and activation potential of T cells. Additionally, FGL1/LAG3 has demonstrated therapeutic potential when combined with targeted therapies, radiotherapy, traditional Chinese medicine, and adoptive cell therapy. Overall, FGL1/LAG3 plays a pivotal role in cancer initiation, progression, diagnosis, treatment, and prognosis.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"344-353"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing colorectal cancer diagnosis: The role of tumor-derived serum galanin and haptoglobin as novel biomarkers.","authors":"Ning Yuan, Ren Ren, Dan Li, Xinmei Liang, Xiaochen Pang, Jun Wang, Xiaodong Feng, Zhijun Zhang","doi":"10.4103/jcrt.jcrt_1742_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1742_24","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a widespread and serious global malignancy. This study aimed to investigate the clinical relevance of galanin (GAL) and haptoglobin (HP) as new diagnostic CRC biomarkers.</p><p><strong>Methods: </strong>An enzyme-linked immunosorbent assay was used to determine the GAL and HP levels in the serum of 88 patient with CRC and 88 healthy controls. The carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) contents were quantitatively evaluated via electrochemiluminescence assay. Receiver operating characteristic (ROC) curves were created to identify the diagnostic importance of single and combined CRC detection. The patients' relevant diagnostic and treatment data were collected from their medical records. Statistical analysis methods were employed to examine the relationship between these indicators and the clinical pathological parameters.</p><p><strong>Results: </strong>Patients with CRC exhibited significantly decreased and increased serum GAL and HP levels, respectively, compared with the healthy controls (P < 0.0001 for both). Furthermore, the HP level was positively correlated with tumor T stage (P = 0.0124). The area under the curve (AUC) of the ROC values for GAL and HP was 0.744 and 0.712, respectively, indicating their diagnostic efficiency. The combination of GAL and HP increased the AUC to 0.753, and when both were integrated with CEA and CA19-9, the AUC further increased to 0.893.</p><p><strong>Conclusion: </strong>This study shows that serum GAL and HP can be used as potential noninvasive diagnostic biomarkers for CRC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"417-424"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}